Objectives: Precise assessment of potential therapeutic synergy, antagonism or indifference between antimicrobial agents currently depends on time-consuming and hard-to-standardize in vitro chequerboard titration methods. We here present a method based on a novel two-dimensional antibiotic gradient technique named Xact TM .
Introduction
Treatment of patients suffering from severe infections is impacted by the speed and accuracy of the assessment of the antimicrobial resistance profile of the causative agent. 1 Hence, the differentiation between susceptible and (multi)drug-resistant bacteria is of immediate clinical relevance. The current threat posed by multidrug resistance urges the development of laboratory methods that document the susceptibility of certain human bacterial pathogens to combinations of antibiotics. Combination therapy may delay the emergence of resistance, widen the spectrum of action of drug combinations and may also diminish the duration of treatment. Confronted with multidrug-resistant bacteria, physicians may ask clinical microbiologists to supply them with such synergy/antagonism testing data.
Whereas conventional, classical 'chequerboard synergy testing' does provide such information, this time-consuming and labour-intensive method cannot be easily performed on a daily routine basis. 2, 3 The methods usually lack sufficient reproducibility and the results may be difficult to interpret. 4 This is especially evident when confronted with multidrug-resistant isolates of Gram-negative bacterial species such as Acinetobacter baumannii, Pseudomonas aeruginosa or other non-fermentative organisms. In several cases, expensive clinical studies intended to show whether or not different drug combinations were synergistic failed to demonstrate such an effect. 5 Costs might have been much less if such studies could have been effectively performed in an in vitro setting. There is therefore a clear need for innovative technologies regarding synergism or antagonism testing for combinations of antimicrobial agents. New approaches have been proposed, e.g. Etest synergy assessment methods. 6, 7 Pankey et al. 6 and Sopirala et al. 7 have shown that when different combinations and coordinations of Etests are used, some of these approaches compare favourably with classical broth dilution-based chequerboard methods. However, the data presented cannot be considered conclusive at that stage, i.e. the stage at which people used two Etests to come to a result (since Etests were not designed to be used in combination, the 'double Etest approach' could only be considered indicative and certainly not final). A new format of the classical Etest, named Xact TM , was described some years ago and here we present a validation of that technology in a routine clinical microbiology setting. 8 -11 Xact TM comprises a 50×50 mm plastic carrier immobilized with a gradient quadrant of two antibiotics of choice arranged in perpendicular alignment, thus giving a predefined concentration pattern with hundreds of unique drug ratios in 1 or 0.5 dilution increments. The carrier needs to be placed onto a bacteriainoculated agar surface and left for 1 h to transfer the gradient imprint to the agar, after which the carrier is removed (see Figure 1 ). After overnight incubation, fractional inhibitory concentration indices (FICIs) are read along the inhibition isobole (see Figure 2 ). 12 Previously, Xact TM has been compared with chequerboard titration using bacterial isolates for several species that were successfully tested in numerous replicates. 9 -11 The reproducibility of Xact TM isoboles and FICI values (n¼ 50) was acceptable with a standard deviation equivalent to ,25% variation from the mean FICI value. Xact TM appeared to be simple to use for the quantification of drug -drug interactions over a wide range of drug ratios and it was concluded that it deserved further investigation as a potential tool for combination testing. To date, such data are still lacking.
We here focused on a panel of multidrug-resistant A. baumannii clinical isolates and, using an Xact TM assay, tested them for potentially synergistic susceptibility to meropenem and colistin. We selected the combination between meropenem and colistin since this is one of the preferred therapeutic combinations against such strains. In addition, colistin resistance fortunately is still rare and in combination with a carbapenem such as meropenem therapeutic success is frequent. van Belkum et al.
Materials and methods

Strains
Staphylococcus epidermidis 1-1478 were used as control strains during the preliminary validation experiments. 9 -11 The A. baumannii strains used in the present validation study (n ¼ 27) are described in Table 1 . This table shows the results of the synergy testing by chequerboard titration and Xact TM testing. Single-plex PCR assays were used to detect the following b-lactamase genes: four carbapenem-hydrolysing oxacillinases (bla OXA-51 , bla OXA-23 , bla OXA-24 and bla OXA-58 ), four metallo-b-lactamase genes (bla IMP , bla VIM , bla SPM and bla NDM ), bla KPC and bla GES . Optimized antibiotic synergy testing 169 
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Antibiotics and configuration
For susceptibility testing of the A. baumannii strains, concentrations of colistin and meropenem were applied in the Xact TM format that equalled the dilutions used in the chequerboard titrations in 2-fold dilutions in Mueller -Hinton broth in 96-well microtitre trays. Different lots of Xact TM quadrants were used. The quadrants were stored at 2208C in the presence of desiccant.
Procedure for the chequerboard titration
Chequerboard was performed in duplo using 10 6 cfu/mL in MuellerHinton broth (BBL). The MICs of meropenem, colistin and meropenem plus colistin at various ratios were read and the FICI calculated. Briefly, per round-bottomed 96-well ELISA plate, a single strain was tested and the inoculum was set at 10 6 cfu/mL in Mueller -Hinton broth. The core antibiotic stock solutions were set at 11 mg/mL for colistin and at 50 mg/mL for meropenem. Per well, 50 mL of the two antibiotic solutions each was mixed with 100 mL of the strain suspension. After 24 h at 378C, plates were read and the last wells without growth were sampled to define the true negative cultures.
Xact
TM procedure
Mueller-Hinton (BBL) agar plates (150 mm) were flooded or streaked with a bacterial inoculum (a 10× diluted 0.5 McFarland suspension) and dried completely at 358C for 15 min. The Xact TM quadrant was applied to the agar surface while its exact position was marked on the back of the plate (Figure 1 ). The quadrant was removed after 1 h. The plate was incubated at 358C for 16 -20 h. The effect of inoculum variation ( 10 5 -10 9 cfu/mL) was studied with E. coli ATCC 25922. Digital pictures of the results were transferred to a computer and interpreted using a reading grid. Then, the demarcation zone of the isobole could be defined by clicking on the screen. The software then automatically calculates the various FICIs for the respective drug ratios. The program also provides a table surveying all results as well as a graph showing FICI versus the ratios of the two drugs used. Plates were also read manually and independently by two technicians with a grid placed on the back of the plate. Inhibition zones provide information on synergistic, additive or antagonistic effects along various concentration ratios of antimicrobials A and B, respectively. The inhibition curves for meropenem and colistin were read where the inhibition curvature intersected the outer edge of the grid (Figure 2) . The FICI was read where the inhibition isobologram intersected the diagonal FICI scale with 2.0 on the scale positioned on the inhibition curve/inhibition van Belkum et al.
curve intersection point (Figure 2) . Sometimes, manual reading using a ruler was preferred for the sake of convenience. The FICI at different antibiotic ratios was read by transposing the FICI scale in a parallel direction. The area of the inhibition isobole that fell in various FICI interpretive sections showed the different types of interactions that occurred at different meropenem/colistin ratios.
Interpretative definitions
Arbitrary definitions were defined-before experiments-as follows: when the FICI was ≤0.5 the antibiotic combination was considered to be synergistic; when the FICI was .0.5 and ≤1.0 the effect of the two antibiotics was considered to be additive; when the FICI was .1.0 and ≤2.0 the antibiotic interaction was indifferent; and, finally, when the FICI was ≥3.0 the antibiotic combination was defined as antagonistic. 13 When groups of strains were compared, the two-sided Fisher exact test was used and P,0.05 was considered to be significant.
Results
Control assays with the dedicated strains indicated that both antibiotics were present in an active form. Previous analyses of inoculum effects on the Xact TM FICI as measured for E. coli ATCC 25922 revealed that within a range between a 1 : 100 dilution of a 0.5 McFarland and a 5 McFarland suspension there was consistent measurement of both the inhibition curve and the FICI. It was concluded that at the level of Xact TM , the inoculum effect was negligible. Similar results were obtained previously with different combinations of antibiotics. 9 -11 This work examined 27 multidrug-resistant A. baumannii strains, most of them isolated from rectal swabs and all collected between 2006 and 2013 in the Hô pital Universitaire de Geneve. All study isolates were resistant to amikacin, ciprofloxacin, ceftazidime and piperacillin/tazobactam. All strains were positive for bla OXA-51 , 13/27 strains carried bla OXA-23 , 2/27 strains carried a bla OXA-24-like gene and 4/27 strains had a bla OXA-58 gene. GES-type carbapenemases were found in three strains. A strain harbouring NDM-1 was identified from two patients. KPC, VIM, IMP and SPM assays were uniformly negative. The MIC of imipenem ranged from 0.38 to 256 mg/L. Of note, the presence of any of these carbapenemase-encoding genes did not correlate with whether a strain's phenotype would show synergism or not. The MIC of meropenem ranged from 0.5 to 256 mg/L. Twenty-six out of 27 isolates were resistant according to EUCAST clinical breakpoints as published for 2014. All study isolates were susceptible to colistin. The MIC of colistin ranged from 0.064 to 0.5 mg/L.
Chequerboard titration and Xact TM testing revealed concordant synergism in 16/25 strains (64%), with two strains being nontestable due to an elevated meropenem MIC. In two strains, discordant results were obtained. Finally, 7/25 (28%) strains were reported as additive in perfect concordance by the two methods. Overall, 23/25 isolates (92%) for which both synergy tests were performed successfully showed full concordance in the comparison between the gold standard method and Xact TM .
Discussion
It has been shown by comparative in vitro testing for carbapenemresistant A. baumannii isolates with multiple resistance traits that synergy between imipenem, amikacin, tobramycin and colistin could be demonstrated for significant percentages of isolates but not for all. 14 -16 The analyses were performed by chequerboard titration and time-kill assays and it was concluded that synergy testing, though technically challenging, might lead to better selection of more adequate therapy. Fortunately, besides the chequerboard titration methods for assessing synergistic activities for antibiotic combinations, simpler alternatives have been proposed over the past years. Still, these methods all share two big shortcomings: first, they only provide information for a fixed antibiotic mixture; and, second, they usually require the very precise positioning of discs or strips that contain fixed amounts of gradients of antibiotics. This is usually cumbersome and non-precise and alternatives are still being sought. We here show that according to chequerboard reference data, the newly developed Xact TM test showed 92% identity with the gold standard assay, a very good level of concordance for testing of Acinetobacter strains. In addition, underscoring the relevance of the Xact TM format, not all strains belonged to a single category of isolates, showing the relevant specificity of the method. However, there was not a single example of antagonism and if this can be verified in more extensive studies, then this would suggest that a combination of colistin and meropenem would be a good antibiotic therapy to start with for treatment of infections caused by multidrug-resistant Acinetobacter. In support of this suggestion, it has been demonstrated that combination therapy with colistin and carbapenems is among the most successful known to date. 17 Finally, the concentrations where synergy was observed were deemed quite compatible with the concentration range across which these antibiotics can be used in patients. However, in the case of the combination of colistin and meropenem the Xact TM format does not allow for the precise assessment of MICs of the individual antibiotics due to interference between the compounds. We have preliminary evidence that the method also works for Burkholderia spp., P. aeruginosa, MSSA, MRSA and a variety of other bacterial and even yeast species (A. van Belkum, D. Halimi, E.-J. Bonetti, G. Renzi, A. Cherkaoui, V. Sauvonnet, R. Martelin, G. Durand, S. Chatellier, G. Zombardi, A. Engelhardt, Å . Karlsson and J. Schrenzel, unpublished results). 18 The Xact TM method is easy to set up and the data generated were convenient to analyse. The continuous and stable gradient generated high precision levels and adequate reproducibility. The test is inherently high throughput since drug-drug interactions could be studied across 225 or 900 drug ratios in 1 or 0.5 dilution increments. One disadvantage is that it will remain unclear whether the effect seen in the growth curves is due to bacteriostatic or bactericidal activity, a feature important in the therapy of multidrug-resistant organisms as a whole.
In comparison with chequerboard titration, Xact TM allowed us to perform three times more analyses during a similar amount of working time, not even including the preparation time for the plates. The assay offered clear potential and added value for routine antibiotic synergy testing and deserves further investigation for combination testing of various drugs and organisms in different configurations. Also, the interaction between antibiotics and enzyme inhibitors (e.g. b-lactams and b-lactamase inhibitors) or antibiotics and antifungals can be subjected to Xact TM -mediated analysis, although this will still require a detailed analysis of the shelf-life of the products. Optimization of the assays can be pursued via intelligent imaging and automation. Finally, the current format offers clear opportunities for the assessment of 
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